Stratatech Corp., a Madison company that produces cell-based skin substitutes for medical research, said a clinical trial has shown that burn patients receiving grafts of its product approached full healing without further skin grafts.The company said all 10 patients in the trial received a single application of its StrataGraft human skin substitute for treatment of severe burns. None required a regrafting of the patient's own tissue over the site after 28 days. All seven patients who were assessed after three months achieved complete wound closure, Stratatech said.
Print to Page
Email to a Friend